|
業務類別
|
Medical Devices |
|
業務概覽
|
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer,pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. |
| 公司地址
| 6272 W. 91st Avenue, Westminster, CO, USA, 80031 |
| 電話號碼
| +1 888 321-5212 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.trisaluslifesci.com |
| 員工數量
| 110 |
| Dr. Richard Marshak, V.M.D. |
Chief Commercial Officer |
-- |
30/04/2025 |
| Mr. Dan Giordano |
Vice President, Finance |
-- |
30/05/2025 |
| Ms. Mary T. Szela |
Chief Executive Officer, President and Director |
美元 601.40K |
05/03/2026 |
| Mr. David Patience |
Chief Financial Officer and Principal Accounting Officer |
-- |
05/03/2026 |
| Ms. Jennifer Stevens |
Chief Regulatory Officer |
-- |
30/04/2025 |
| Ms. Jodi Devlin |
Chief of Clinical Operations |
美元 501.71K |
30/04/2025 |
| Mr. Bryan F. Cox |
Chief of Research |
-- |
30/04/2025 |
|
|
| Mr. Kerry R. Hicks |
Independent Director |
05/03/2026 |
| Mr. Mats L. Wahlstrom |
Chairman of the Board |
05/03/2026 |
| Dr. Gary Gordon |
Director |
05/03/2026 |
| Ms. Mary T. Szela |
Chief Executive Officer, President and Director |
05/03/2026 |
| Mr. Michael P. Stansky |
Director |
09/02/2026 |
| Mr. David J. Matlin |
Independent Director |
05/03/2026 |
| Mr. William Valle |
Director |
05/03/2026 |
|
|
|
|
